HUE053414T2 - N-(fenilszulfonil)benzamid származékok mint Bcl-2 inhibitorok - Google Patents
N-(fenilszulfonil)benzamid származékok mint Bcl-2 inhibitorokInfo
- Publication number
- HUE053414T2 HUE053414T2 HUE17754889A HUE17754889A HUE053414T2 HU E053414 T2 HUE053414 T2 HU E053414T2 HU E17754889 A HUE17754889 A HU E17754889A HU E17754889 A HUE17754889 A HU E17754889A HU E053414 T2 HUE053414 T2 HU E053414T2
- Authority
- HU
- Hungary
- Prior art keywords
- phenylsulfonyl
- bcl
- inhibitors
- benzamide derivatives
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US201762454101P | 2017-02-03 | 2017-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053414T2 true HUE053414T2 (hu) | 2021-06-28 |
Family
ID=59677319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17754889A HUE053414T2 (hu) | 2016-08-05 | 2017-08-04 | N-(fenilszulfonil)benzamid származékok mint Bcl-2 inhibitorok |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (hu) |
| EP (3) | EP3569601B1 (hu) |
| JP (2) | JP6651180B2 (hu) |
| KR (2) | KR102429704B1 (hu) |
| CN (2) | CN109311871B (hu) |
| AU (2) | AU2017305508B2 (hu) |
| BR (1) | BR112019001666A2 (hu) |
| CA (1) | CA3031419C (hu) |
| CY (1) | CY1123859T1 (hu) |
| DK (1) | DK3494115T3 (hu) |
| ES (1) | ES2849959T3 (hu) |
| HR (1) | HRP20202073T1 (hu) |
| HU (1) | HUE053414T2 (hu) |
| IL (2) | IL264059B (hu) |
| LT (1) | LT3494115T (hu) |
| MX (2) | MX2019001391A (hu) |
| PE (1) | PE20190711A1 (hu) |
| PH (1) | PH12019500231A1 (hu) |
| PT (1) | PT3494115T (hu) |
| RS (1) | RS61821B1 (hu) |
| RU (3) | RU2722560C1 (hu) |
| SA (1) | SA519401020B1 (hu) |
| SG (2) | SG10201913643YA (hu) |
| SI (1) | SI3494115T1 (hu) |
| WO (1) | WO2018027097A1 (hu) |
| ZA (2) | ZA201900240B (hu) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156398A1 (en) * | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| RU2722560C1 (ru) * | 2016-08-05 | 2020-06-01 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| PT3612531T (pt) * | 2017-04-18 | 2022-10-04 | Shanghai Fochon Pharmaceutical Co Ltd | Agentes indutores de apoptose |
| EP3788042A4 (en) | 2018-04-29 | 2022-01-26 | BeiGene, Ltd. | BCL-2 INHIBITORS |
| CN114522167A (zh) * | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| BR112020019134A2 (pt) * | 2018-07-31 | 2021-02-09 | Ascentage Pharma (Suzhou) Co., Ltd. | produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos |
| JP7058345B2 (ja) * | 2018-07-31 | 2022-04-21 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 |
| CA3095699A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN111214471B (zh) * | 2018-11-23 | 2021-04-02 | 苏州亚盛药业有限公司 | 药物组合物及其用途 |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| US20220305034A1 (en) * | 2019-06-12 | 2022-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| CN112168830B (zh) * | 2019-07-02 | 2022-01-25 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| WO2021018240A1 (en) * | 2019-07-31 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| TW202134239A (zh) * | 2019-11-27 | 2021-09-16 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| TWI777321B (zh) * | 2019-12-04 | 2022-09-11 | 大陸商蘇州亞盛藥業有限公司 | 藥物組合及其用途 |
| CA3160417A1 (en) | 2019-12-06 | 2021-06-10 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
| EP3914596A4 (en) * | 2020-03-06 | 2022-04-20 | Ascentage Pharma (Suzhou) Co., Ltd. | CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS OR THEIR SALTS OR SOLVATES |
| CN115244051A (zh) * | 2020-03-12 | 2022-10-25 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| WO2022002178A1 (en) * | 2020-07-01 | 2022-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| JP2023533735A (ja) * | 2020-07-10 | 2023-08-04 | 江蘇恒瑞医薬股▲ふん▼有限公司 | スルホニルベンズアミド系誘導体及びその複合体、その調製方法並びにその応用 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| WO2022037683A1 (en) * | 2020-08-21 | 2022-02-24 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2022037684A1 (en) * | 2020-08-21 | 2022-02-24 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating systemic lupus erythematosus |
| JP2023551056A (ja) * | 2020-11-25 | 2023-12-06 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 固体分散体、医薬製剤、その製造方法及び応用 |
| CN114681458B (zh) * | 2020-12-28 | 2023-07-18 | 苏州亚盛药业有限公司 | 治疗多发性硬化症的方法 |
| EP4298098A1 (en) * | 2021-02-01 | 2024-01-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Sulfonyl benzamide derivatives as bcl-2 inhibitors |
| WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| CN117957018A (zh) | 2021-08-02 | 2024-04-30 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US7842681B2 (en) | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
| AU2007329458A1 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EP3101019A1 (en) | 2008-12-05 | 2016-12-07 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| KR20110116161A (ko) | 2009-01-19 | 2011-10-25 | 아보트 러보러터리즈 | 암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| US9045800B2 (en) | 2009-02-11 | 2015-06-02 | Abbvie Inc. | Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers |
| TWI561523B (en) | 2009-05-26 | 2016-12-11 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| WO2012058392A1 (en) | 2010-10-29 | 2012-05-03 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
| SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| SI2642999T1 (sl) | 2010-11-23 | 2017-01-31 | Abbvie Ireland Unlimited Company | Postopki zdravljenja z uporabo selektivnih Bcl-2 inhibitorjev |
| US10327687B2 (en) | 2015-12-30 | 2019-06-25 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors |
| RU2722560C1 (ru) | 2016-08-05 | 2020-06-01 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 |
-
2017
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 BR BR112019001666A patent/BR112019001666A2/pt active Search and Examination
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active IP Right Grant
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en unknown
- 2017-08-04 MX MX2019001391A patent/MX2019001391A/es unknown
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active IP Right Grant
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
- 2020-10-23 RU RU2020134802A patent/RU2020134802A/ru unknown
- 2020-12-29 HR HRP20202073TT patent/HRP20202073T1/hr unknown
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053414T2 (hu) | N-(fenilszulfonil)benzamid származékok mint Bcl-2 inhibitorok | |
| IL272910A (en) | Ectonucleotide pyrophosphate-phosphodiesterase 1 (ENPP-1) inhibitors and their uses | |
| HK1249101A1 (zh) | 作為magl抑制劑的1，1，1-三氟-3-羥基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羥基丁-2-基氨基甲酸酯衍生物 | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| DK3442947T3 (da) | Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere | |
| DK3440076T3 (da) | Heterocykliske amider, der kan anvendes som proteinmodulatorer | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
| IL263739B (en) | History of n-(converted-phenyl)-sulfonamide as kinase inhibitors | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3313833T3 (da) | Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| DK3277682T3 (da) | 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere | |
| DK3319970T3 (da) | Pyrido-oxazinonderivater som tnap-hæmmere | |
| ZA202002786B (en) | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors | |
| DK3712162T3 (da) | Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf | |
| MA41557A (fr) | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 | |
| DK3724196T3 (da) | Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551634T3 (da) | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551633T3 (da) | Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3224253T3 (da) | Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer |